The US FDA has recently issued a warning that Lyrica, Neurontin and other anticonvulsants could cause increase a patient’s risk of suicidal thoughts and behaviors. Lyrica is the only drug to have FDA approval for the treatment of Fibromyalgia and both Lyrica and Neurontin are used in the treatment of neuropathic pain.

An FDA study of 11 anticonvulsants/antiepileptics found that people taking the medications had double the risk of suicidal thoughts and behaviors compared to those taking a placebo. The risk corresponds to an estimated 2.1 per 1,000 more patients in the drug treatment groups who experienced suicidality than in the placebo groups.

The FDA warns that patients who are currently taking antiepileptic medicines should not make any changes without first talking to their health care provider. It can be dangerous to come off these medications suddenly without medical supervision. Health care providers should notify patients, their families, and caregivers of the potential for an increase in the risk of suicidal thoughts or behaviors so that patients may be closely observed for notable changes in behavior.

 The medications studied were:

Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, Tegretol XR)
Felbamate (marketed as Felbatol)
Gabapentin (marketed as Neurontin)
Lamotrigine (marketed as Lamictal)
Levetiracetam (marketed as Keppra)
Oxcarbazepine (marketed as Trileptal)
Pregabalin (marketed as Lyrica)
Tiagabine (marketed as Gabitril)
Topiramate (marketed as Topamax)
Valproate (marketed as Depakote, Depakote ER, Depakene, Depacon)
Zonisamide (marketed as Zonegran)

Some of these drugs are also available in generic form. Although only these drugs were analysed, the FDA says that it “expects that all medications in the antiepileptic class share the increased risk of suicidality.”